Trade Monopar Therapeutics Inc. - MNPR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | - | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 1.30-4.88 |
Average Volume (10 days) | 102.83K |
Average Volume (3 months) | 754.41K |
Market Cap | 18.34M |
P/E Ratio | -100.00K |
Shares Outstanding | 13.19M |
Revenue | N/A |
EPS | -0.83 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | May 10, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|
Monopar Therapeutics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, April 3, 2023 | ||
Time (UTC) 17:00 | Country US
| Event Monopar Therapeutics Inc at Jefferies Radiopharma Innovation Summit Monopar Therapeutics Inc at Jefferies Radiopharma Innovation SummitForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | |||
Total Operating Expense | 10.5369 | 9.12725 | 6.50888 | 4.32376 | 3.33115 |
Selling/General/Admin. Expenses, Total | 2.94528 | 2.63404 | 2.44368 | 2.35524 | 1.55669 |
Research & Development | 7.5916 | 6.49321 | 4.0652 | 1.96852 | 1.77445 |
Operating Income | -10.5369 | -9.12725 | -6.50888 | -4.32376 | -3.33115 |
Interest Income (Expense), Net Non-Operating | 0.02124 | 0.02402 | 0.0819 | 0.09889 | 0.10322 |
Net Income Before Taxes | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Net Income After Taxes | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Net Income Before Extra. Items | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Net Income | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Income Available to Common Excl. Extra. Items | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Income Available to Common Incl. Extra. Items | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Diluted Net Income | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Diluted Weighted Average Shares | 12.7182 | 12.4722 | 10.9583 | 10.421 | 10.421 |
Diluted EPS Excluding Extraordinary Items | -0.82682 | -0.72988 | -0.57533 | -0.40542 | -0.30975 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | -0.82682 | -0.72988 | -0.57533 | -0.40542 | -0.30975 |
Other, Net | 0 | 0.1224 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 2.909 | 2.40735 | 2.76335 | 2.45719 | 2.68112 |
Selling/General/Admin. Expenses, Total | 0.80874 | 0.67512 | 0.68488 | 0.77925 | 0.69844 |
Research & Development | 2.10297 | 1.73223 | 2.07847 | 1.67793 | 1.98268 |
Operating Income | -2.909 | -2.40735 | -2.76335 | -2.45719 | -2.68112 |
Interest Income (Expense), Net Non-Operating | 0.01266 | 0.0077 | 0.00042 | 0.00046 | 0.00053 |
Net Income Before Taxes | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Net Income After Taxes | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Net Income Before Extra. Items | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Net Income | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Income Available to Common Excl. Extra. Items | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Income Available to Common Incl. Extra. Items | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Diluted Net Income | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Diluted Weighted Average Shares | 12.8795 | 12.7547 | 12.6324 | 12.6044 | 12.5919 |
Diluted EPS Excluding Extraordinary Items | -0.22488 | -0.18814 | -0.21872 | -0.19491 | -0.21288 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Diluted Normalized EPS | -0.22488 | -0.18814 | -0.21872 | -0.19491 | -0.21288 |
Other Operating Expenses, Total | -0.00271 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 20.5216 | 16.7998 | 13.2296 | 7.25222 | 9.13124 |
Cash and Short Term Investments | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
Cash & Equivalents | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
Other Current Assets, Total | 0.21775 | 0.06269 | 0.01571 | 0.35945 | 0.14934 |
Total Assets | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
Other Long Term Assets, Total | 0 | 0.06886 | 0.12238 | 0.06573 | 0.80003 |
Total Current Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Payable/Accrued | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 18.9411 | 15.692 | 12.6279 | 6.9184 | 9.6194 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.0126 | 0.01145 | 0.01059 | 0.00929 | 0.00929 |
Additional Paid-In Capital | 60.22 | 47.8736 | 38.5088 | 28.5672 | 28.0379 |
Other Equity, Total | -0.00316 | -0.00787 | -0.01097 | -0.0024 | -18.4278 |
Total Liabilities & Shareholders’ Equity | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
Total Common Shares Outstanding | 12.5981 | 11.4535 | 10.6215 | 10.421 | 10.421 |
Retained Earnings (Accumulated Deficit) | -41.2884 | -32.1852 | -25.8806 | -21.6557 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 18.0127 | 20.5216 | 22.4484 | 24.3884 | 25.8377 |
Cash and Short Term Investments | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
Cash & Equivalents | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
Other Current Assets, Total | 0.19364 | 0.21775 | 0.1068 | 0.09556 | 0.11457 |
Total Assets | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
Other Long Term Assets, Total | 0 | 0.06886 | 0.06886 | 0.06886 | |
Total Current Liabilities | 1.07412 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Payable/Accrued | 1.04815 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.09946 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 16.9669 | 18.9411 | 21.2773 | 23.3536 | 25.1003 |
Common Stock | 0.01262 | 0.0126 | 0.01259 | 0.01258 | 0.01257 |
Additional Paid-In Capital | 60.7031 | 60.22 | 59.8776 | 59.4955 | 59.162 |
Retained Earnings (Accumulated Deficit) | -43.7451 | -41.2884 | -38.6078 | -36.1493 | -34.0692 |
Other Equity, Total | -0.00374 | -0.00316 | -0.00515 | -0.00516 | -0.0051 |
Total Liabilities & Shareholders’ Equity | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
Total Common Shares Outstanding | 12.6206 | 12.5981 | 12.5906 | 12.5827 | 12.5699 |
Property/Plant/Equipment, Total - Net | 0.05369 | ||||
Accrued Expenses | 0.02598 | ||||
Other Liabilities, Total | 0.02534 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Cash From Operating Activities | -7.22856 | -7.3174 | -4.66227 | -3.01768 | -2.68049 |
Non-Cash Items | 1.64126 | 1.46805 | 1.19849 | 1.01117 | 0.52933 |
Changes in Working Capital | 1.64582 | 0.31777 | 0.44381 | 0.19602 | 0.01811 |
Cash From Financing Activities | 0.03287 | 10.8795 | 8.18212 | 9.34741 | -0.20627 |
Financing Cash Flow Items | -0.07663 | -0.06325 | -0.11557 | -0.98481 | -0.20627 |
Issuance (Retirement) of Stock, Net | 0.10951 | 10.9428 | 8.17529 | 10.3322 | 0 |
Net Change in Cash | -12.1177 | 3.56676 | 3.52318 | 6.32116 | -2.88915 |
Foreign Exchange Effects | -0.00348 | 0.00462 | 0.00333 | -0.00857 | -0.0024 |
Cash Taxes Paid | 0 | -0.0111 | |||
Issuance (Retirement) of Debt, Net | 0.1224 | ||||
Cash From Investing Activities | -4.91851 | ||||
Other Investing Cash Flow Items, Total | -4.91851 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -10.5156 | -7.6193 | -5.21965 | -2.45672 | -9.10322 |
Cash From Operating Activities | -7.22856 | -5.92675 | -3.77828 | -2.4675 | -7.3174 |
Non-Cash Items | 1.64126 | 1.24785 | 0.85711 | 0.49981 | 1.46805 |
Changes in Working Capital | 1.64582 | 0.4447 | 0.58427 | -0.51059 | 0.31777 |
Cash From Financing Activities | 0.03287 | -0.10586 | -0.08213 | -0.01667 | 10.8795 |
Financing Cash Flow Items | -0.07663 | -0.10603 | -0.08217 | -0.01667 | -0.06325 |
Issuance (Retirement) of Stock, Net | 0.10951 | 0.00017 | 0.00004 | 0 | 10.9428 |
Foreign Exchange Effects | -0.00348 | 0.04521 | 0.0201 | -0.00066 | 0.00462 |
Net Change in Cash | -12.1177 | -5.98741 | -3.8403 | -2.48483 | 3.56676 |
Issuance (Retirement) of Debt, Net | |||||
Cash From Investing Activities | -4.91851 | ||||
Other Investing Cash Flow Items, Total | -4.91851 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Tacticgem LLC | Corporation | 31.1621 | 4111273 | 0 | 2022-04-15 | LOW |
Gem Pharmaceuticals LLC | Corporation | 23.1589 | 3055394 | 0 | 2022-04-15 | LOW |
Hendricks (Diane) | Individual Investor | 3.553 | 468750 | 0 | 2022-04-15 | LOW |
Brown Michael J | Individual Investor | 1.711 | 225730 | 2859 | 2022-12-31 | LOW |
Tactic Pharma LLC | Corporation | 1.2633 | 166667 | 0 | 2022-04-15 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.7578 | 99976 | 97 | 2022-12-31 | LOW |
Robinson (Chandler D) | Individual Investor | 0.5816 | 76730 | 4396 | 2023-01-01 | LOW |
Starr (Christopher M) | Individual Investor | 0.4937 | 65130 | 2859 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3175 | 41892 | 2721 | 2022-12-31 | LOW |
Cittadine (Andrew) | Individual Investor | 0.2038 | 26894 | 2656 | 2022-12-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1735 | 22884 | -293 | 2022-12-31 | LOW |
Mazar (Andrew Paul) | Individual Investor | 0.1677 | 22125 | 0 | 2022-04-15 | LOW |
Klausner (Arthur J) | Individual Investor | 0.1571 | 20730 | 2859 | 2022-12-31 | LOW |
Tsuchimoto (Kim R) | Individual Investor | 0.1403 | 18507 | 728 | 2023-01-01 | MED |
Anderson (Raymond William) | Individual Investor | 0.1268 | 16730 | 2859 | 2022-12-31 | MED |
Northern Trust Global Investments | Investment Advisor | 0.1 | 13197 | 0 | 2022-12-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.0303 | 4000 | 0 | 2022-12-31 | LOW |
UBS Financial Services, Inc. | Investment Advisor | 0.0239 | 3154 | -2245 | 2022-12-31 | LOW |
Tower Research Capital LLC | Hedge Fund | 0.0215 | 2831 | -300 | 2022-12-31 | HIGH |
Paragon Wealth Strategies, LLC | Investment Advisor | 0.0004 | 58 | 0 | 2022-12-31 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Monopar Therapeutics Inc. Company profile
About Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Monopar Therapeutics Inc revenues was not reported. Net loss increased 54% to $6.4M. Higher net loss reflects Interest income decrease of 67% to $23K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.39 to -$0.52.
Industry: | Biotechnology & Medical Research (NEC) |
1000 Skokie Blvd Ste 350
WILMETTE
ILLINOIS 60091-1146
US
Income Statement
- Annual
- Quarterly
News

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com